Previous 10 | Next 10 |
NEW YORK, June 28, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the Company ha...
~1 in 5 people with diabetes or pre-diabetes have Diabetic Cardiomyopathy, a serious and progressive disease that limits the heart’s ability to function People with diabetes or pre-diabetes who have Diabetic Cardiomyopathy are at high risk for developing overt heart fai...
NEW YORK, June 21, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced a Product Theater p...
syahrir maulana/iStock via Getty Images Applied Therapeutics (APLT) has added ~6.8% in the pre-market after the company announced that the FDA has granted the Fast Track designation to AT-007 for the treatment of Galactosemia, a rare metabolic disorder. Fast Track designation is des...
NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the U.S. Food ...
NEW YORK, June 01, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will p...
NEW YORK, May 19, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will pr...
Applied Therapeutics (APLT): Q1 GAAP EPS of -$1.00 beats by $0.10.Cash and cash equivalents and short-term investments of $148.1M.Press Release For further details see: Applied Therapeutics EPS beats by $0.10
Phase 2 pilot study of AT-007 initiated in patients with SORD Deficiency NDA submission for AT-007 in Galactosemia expected no later than Q3 2021; commercial preparations ongoing Completion of enrollment in ARISE-HF Phase 3 global registrational study of AT-001 in Diabet...
NEW YORK, April 07, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced a poster presentat...
News, Short Squeeze, Breakout and More Instantly...
Applied Therapeutics Inc. Company Name:
APLT Stock Symbol:
NYSE Market:
Applied Therapeutics Inc. Website:
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the Company was adde...
2024-06-11 10:45:04 ET Palo Alto Networks Inc (PANW) PANW is trading UP for the last 5 days, and it at trading at $313.28 with volume of 858,188 and a one day change of $4.23 (1.37%). Palo Alto Networks Inc has a 52-week low of 201.17 and a 52-week high of $380.84. The business's 50...